Innovative Business Plan Related to Biology
In today's society, there are more and more situations that require the use of a business plan, which can help entrepreneurs to know themselves more clearly. Do you know the format of the business plan? The following is the innovative business plan related to biology that I help you organize, just for reference, welcome to read.
with the biology of the innovative entrepreneurship plan 1
I. Project Introduction:
1. Definition: Biopharmaceutical refers to the use of microbiology, biology, medicine, biochemistry, and other research results from the living organisms, biological tissues, cells, body fluids, and so on, the comprehensive use of microbiology, chemistry, biochemistry, biotechnology, biotechnology and other scientific principles, including the use of microorganisms, chemistry, biochemistry, biotechnology, pharmacology and other scientific principles. Technology, pharmacy and other scientific principles and methods for the manufacture of a class of products for prevention, treatment and diagnosis.
2. Raw materials: the raw materials of biological drugs are mainly natural biological materials, including microorganisms, human body, animals, plants, marine organisms and so on. With the development of biotechnology, purposeful artificial production of biological raw materials has become the main source of raw materials for biopharmaceuticals.
3. Product composition: vitamins, erythromycin, Zeomicin, etc., injectable penicillin, streptomycin, gentamicin, etc. is produced by fermentation with different microorganisms. The vast majority of antibiotics that have been used in medicine come from microorganisms, and each product has strict production standards. Predicting the progress of biopharmaceutical research, it will be widely used in the treatment of cancer, AIDS, coronary heart disease, anemia, dysplasia, diabetes and many other diseases.
Second, the service profile:
1. Service object: hospitals and other medical institutions and the demand for biopharmaceutical products and direct users.
2. Service institutions: Specialized service institutions should be set up, such as specialized consulting and after-sales service institutions in hospitals and residential areas.
3. Service personnel: cultivate a specialized team, mainly including sales staff, drug experts, lawyers, managers, information collectors, etc., focusing on the division of labor, cooperation and coordination.
4. Spirit of service: form a unique service culture, establish a first-class service image, and adhere to the principle of service first.
5. Service content: R & D departments should focus on research and development of new technologies to produce new products to satisfy consumers and meet their new needs; consulting organizations are mainly responsible for answering the hospital doctors and patients and residents of the residential area of the drug-related information, and at the same time to play a role in the promotion of new products and the collection of information on their higher needs, in order to facilitate the company to develop new medicines, the promotion of new medicines and to further expand the product market; after-sales service organizations are mainly responsible for the promotion of new products and to further broaden the market for the product. After-sales service organizations are mainly responsible for collecting the effect of the use of drugs, feedback to the headquarters and R & D departments, while dealing with some after-sales problem analysis and investigation and try to reduce the adverse effects.
6. Service mode: to establish a two-way contact between service personnel and consumers, strengthen communication and mutual supervision of the harmonious atmosphere.
Third, market analysis and forecast:
1. Market environment analysis: the camp of biological drugs is very large, and the development is also very fast. At present, half of the world's pharmaceutical products have been biosynthesis, especially the synthesis of complex molecular structure of the drug, it is not only easier than the chemical synthesis method, but also has a higher economic efficiency. In the past half century, a series of breakthrough applications of microbial transformation in drug development have created tremendous medical value and economic benefits for the pharmaceutical industry.
(1) political and legal environment: biopharmaceutical technology content is high, so the technology is highly patented, so biopharmaceuticals in the legal barriers are very high, it is more difficult to enter.
(2) economic environment: with the human society . Rapid development, economic development is unprecedented, people can have more financial ability to invest in medical and health care, while science and technology is changing rapidly, the technology of biopharmaceuticals will gradually mature and updated, so from the general trend, biopharmaceuticals will have a broad market demand.
(3) Social culture: with the improvement of people's living standards, people pay more attention to their own health problems, so biopharmaceuticals can be very good to meet this demand, and there is no substitute.
(4) Technical analysis: the technical requirements of biopharmaceuticals are very high, not only to prevent new competitors from joining, but also in the leading technology can be in the existing competitive conditions of the industry pre-emptive.
2. Market Demand Analysis: As there are many product categories of biopharmaceuticals, the market demand for biopharmaceuticals is broad and diversified, such as therapeutic drugs to meet the needs of patients' treatment, and health care drugs for the vast majority of the population with a sense of health care to promote the use of the majority of the population. From the current point of view, many people are more or less accustomed to using medicines, and many medicines are commonly kept at home. In terms of people's general health condition, many people are in the sub-health stage, coupled with the decline in people's overall physical quality, people have become somewhat dependent on drugs. Whether for the treatment of disease, or for the prevention of disease or other unhealthy conditions, people will choose to use drugs or other health care products, so the products of biopharmaceuticals will also appear in some of the gifts and exchanges. In the long run, with the progress of human society and the rapid development of economy, people will pay more and more attention to their own health, and with the improvement of people's life expectancy, the aging of the population is becoming more and more prominent, and the demand for biopharmaceutical products for the elderly will be a major demand. In addition, with the development of science and technology, people's demand for biopharmaceutical products will be continuously satisfied. Comprehensive analysis of the above, we can draw a conclusion: the biopharmaceutical market is vast potential, and has the possibility of expansion.
3. Market competition analysis: from the characteristics of the biopharmaceutical industry can be seen that this industry is a technology-intensive industry, and both capital-intensive industry, so the market competitiveness of biopharmaceutical companies is mainly reflected in the enterprise's R & D and capital and scale. I will analyze these three aspects, first of all, technology is the fundamental survival of biopharmaceutical companies, no advanced and updated technology is difficult to get a foothold in this industry, even if the temporary survival can not get rid of the fate of the final elimination. Speaking of technology, we can not talk about innovation, biopharmaceutical companies need to have the ability to innovate and a group of innovative research and development personnel and teams. Then, the biopharmaceutical enterprise should have enough capital flow, and must ensure the operation of the R & D funds. If there is not enough capital, then there is a risk of being limited in competition. Finally, the size of the biopharmaceutical enterprise is a very important issue because it is both a result of the first two, but also can promote the better development and goal achievement of both from the side. The size of the enterprise should be appropriate to ensure normal operation and at the same time have the possibility of further development. Looking at the companies in the biopharmaceutical industry nowadays, they are very competitive in general, but all of them are able to have some benefits. These companies are trying to make themselves able to stand out, so they are all working on these three aspects, hoping for a breakthrough.
Four, marketing strategy.
1. Sales channels: principle (according to different products to develop different sales strategies and programs.). The marketing system is structured to establish a sales system by object and a marketing system by product, forming a marketing network with matrix coverage.)
(1) For therapeutic and diagnostic drugs, the company should promote them to medical institutions such as major hospitals and major pharmacies, and at the same time provide appropriate feedback and improvement through the use of patients.
(2) For health care products, the company should march towards the health care market and take the distribution approach to promote in major supermarkets and other retail parties.
2. Sales plan: (1) the establishment of a strong marketing team we attach importance to the cultivation of a high-quality, team spirit of sales engineers and marketing managers team, attach importance to the discovery and cultivation of strategic marketing management talent and international marketing talent. We want to build a marketing team with a long-term goal, motivated and driven by *** same career, responsibility and honor.
(2) General discussion to establish the marketing program.
(3) Implementation of the program.
(4) carry out market research, collect sales information, summarize the pros and cons of the marketing program, overall discussion for improvement.
3. Customer relations: both to ensure communication and contact with large customers, but also to develop relationships with small and medium-sized customers.
(1) the company should be close contact with large customers, not only business contacts, but also a deeper relationship to ensure that the company's sales performance and profits.
(2) the company should focus on keeping in touch with small and medium-sized customers, although they are not currently considered large customers, but in the long run, the company's future development of the market, to broaden the business, these customers have a greater potential for development.
Fifth, the company's strategy and management
1. Company culture: resources will be depleted, only the culture will be endless. All products are created by human wisdom. Spirit can be transformed into matter, and material civilization is conducive to consolidating spiritual civilization. We adhere to the policy of promoting material civilization through spiritual civilization. Culture here contains not only knowledge, technology, management and sentiment ...... but also all the intangible factors that promote the development of productive forces.
2. Corporate strategy: located in the related diversification strategy, that is, biopharmaceutical companies not only have the core competitiveness of biopharmaceutical products, but also to broaden the development space. Comparing several corporate strategies, the related diversification strategy is a better corporate strategy. First, it can avoid entering unfamiliar industries; then, it can complement the core industry; finally, the related diversification strategy is relatively less risky.
3. Organizational structure: The basic organizational structure of the company will be a two-dimensional structure: divisions by strategic businesses and regional companies by regions. The divisions assume the responsibilities of development, production, sales and customer service within the company's defined scope of operation; the regional companies effectively utilize the company's resources to operate within the company's defined regional markets. Both business divisions and regional companies are profit centers and bear the responsibility for actual profits. The company's management resources, research resources, production management resources, market resources, financial resources, human resources and information resources ...... are the company's public **** resources. In order to improve the efficiency of public **** resources, it is necessary to conduct an audit. The corresponding departments are organized according to the principle of functional specialization, forming the main body of the company's organizational structure.
4. Performance appraisal and reward and punishment system:
The company implements a strict performance appraisal system, not only to have the company's management to assess and review the staff, but also to listen to the staff's own introspection and evaluation. Employee performance appraisal should not only be linked to the work performance, but also take into full consideration of the employee's own ability and consumer evaluation of employee services.
Reward and punishment system should adhere to the clear distinction between reward and punishment, selfless, adhere to the fair, just and open, listen to the views of employees and management. At the same time, the form of rewards and punishments require diversification, according to different behaviors to be rewarded and punished.
5. Personnel training: Regular training for staff and management in order to enhance their quality and better contribute to the company.
VI. Financial Analysis
1. Initial Cost
(1) Acquisition of plant and production line: 5 million
(2) Recruitment of staff: 2 million
(3) R & D staff: 2 million
(4) Working Capital: 5 million
2. Finance staff for statistics.
3. Investment analysis: the basic positioning for the production of health care products, when production reaches a certain scale, in-depth investment in other biopharmaceutical products.
VII. Risk analysis
This industry has high requirements for technology and capital, so the beginning of the crowded from other peer companies, and some details are not clearly understood, as well as financial problems may bring risks to invest in this industry.
Eight, legal analysis
Technology patents is a very important issue, the initial stage to avoid getting caught in the legal vortex of patent theft, strict production and management, to prevent product quality problems, to maintain a good corporate image.
With biological innovation business plan 2Industry Background:
Biochip this is known as the 21st century the most promising change in human life of the new technology, however, due to the high cost of its manufacturing, low accuracy, etc. has not been widely used, and our project solves the industry's key **** problem.
Technical Advantages:
The Biochip Sampler is developed by Prof. Tian Zhaowu's group at the State Key Laboratory of Physical Chemistry of Solid Surfaces, Xiamen University, an academician of the Chinese Academy of Sciences (CAS), after years of research and development, and has been awarded the national patent for the invention (Patent No.: ZL02126729.1), which is used in the manufacture of biochips. The core component is the integrated dot pattern block.
The powerful advantages of this product are:
1. Accuracy: high precision of sampling, greatly improving the accuracy of biochip detection.
2, efficiency: no pre-sampling, the integrated sampling block is a disposable product, no need to clean, to avoid cross-contamination; the use of micro-liquid transfer technology, the amount of reagents consumed is very small.
3, price: compared to the traditional millions of dollars of an instrument, a few thousand dollars a sampling steel needle, the base point of the sampling instrument is only 300,000 yuan a piece, the integrated sampling block is only 1,000 yuan a piece, according to the need to replace the traditional technology of dozens of hundreds of steel needles, a substantial reduction in the manufacturing cost of biochips.
Competitive Advantages:
1. Advanced Technology: Our products have been developed over the years, and are highly original and leading in China.
2. Strong R&D capability: we rely on the State Key Laboratory of Solid Surface Physical Chemistry of Xiamen University, which has strong scientific research strength.
3. Perfect service system: including the establishment of an information platform, the implementation of training programs, as well as the establishment of offices, technical service centers and hotlines.
Market Prospects:
International surveys show that the current world biochip market is growing at a rate of 20% per year, and our country's rate is higher than that due to the impact of policies and economic aspects; therefore, the market has a broad prospect. When our technology is commonly used, making the medical chip market really open, the industry to maturity, the market will show explosive growth. In the market survey, 80% of the respondents said they would like to try the base point products, and we are in the process of negotiating with Shenzhen Yaneng to cooperate in trial production.
Investment Analysis:
The project's NPV = 2.06 million yuan (R = 15%, n = 5 years), the internal rate of return of 29%, the payback period of only about 4 years. For the venture capitalists, they only need to invest 1.575 million yuan in the initial stage of the project, but they can get a cumulative dividend of 2.69 million yuan in 5 years, and the share of net assets at the end of the period is also as high as 2.98 million yuan; the high payoffs brought about by the high payoffs greatly satisfy the requirements of their low investment and high returns.
;